Semaglutide vs Tirzepatide
A side-by-side comparison of Semaglutide and Tirzepatide, including efficacy data, side effects, dosing, and cost.
Feature
Semaglutide
Tirzepatide
Drug Class
GLP-1 receptor agonist
GLP-1 and GIP dual receptor agonist
Brand Names
Ozempic, Wegovy, Rybelsus
Mounjaro, Zepbound
Form
Once-weekly injection (Ozempic, Wegovy) or daily tablet (Rybelsus)
Once-weekly injection
Dosing
0.25 mg → 0.5 mg → 1 mg → 2 mg (weekly injection); 3 mg → 7 mg → 14 mg (daily tablet)
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg (weekly)
FDA Approval
Type 2 diabetes (Ozempic, Rybelsus); Chronic weight management (Wegovy)
Type 2 diabetes (Mounjaro); Chronic weight management (Zepbound)
Efficacy
Average 15-17% body weight loss over 68 weeks (STEP trials)
Average 20-22% body weight loss over 72 weeks (SURMOUNT trials)
Cost
$900-$1,400/month without insurance
$1,000-$1,500/month without insurance
Semaglutide Side Effects
- •Nausea
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
- •Headache
Tirzepatide Side Effects
- •Nausea
- •Diarrhea
- •Decreased appetite
- •Vomiting
- •Constipation
- •Indigestion
Which one should you choose?
The best medication depends on your health goals, insurance coverage, and how your body responds. Semaglutide is a glp-1 receptor agonist, while Tirzepatide is a glp-1 and gip dual receptor agonist, which can affect both efficacy and side effects.
Always consult your healthcare provider before starting or switching medications.